Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Clinical Drug Investigation
|
November 4, 2024
Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers
Mikael Sunnåker, Chandrali Bhattacharya, Karin Nelander, et al.
British Journal of Clinical Pharmacology
|
June 3, 2024
A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
Jane Knöchel, Vijender Panduga, Karin Nelander, et al.
British Journal of Clinical Pharmacology
|
August 12, 2024
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
Chandrali S Bhattacharya, Patricia Ely Pizzato, Maria Heijer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 18, 2025
A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis
Javier Armisen, Armando Flor, John Eriksson, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
October 22, 2020
INEXAS: A Phase 2 Randomized Trial of On-demand Inhaled Interferon Beta-1a in Severe Asthmatics
Christopher McCrae, Marita Olsson, Per Gustafson, et al.
American Journal of Respiratory and Critical Care Medicine
|
August 19, 2020
A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma
Ioannis Psallidas, Vibeke Backer, Piotr Kuna, et al.
Drug Discovery Today
|
June 4, 2013
Model-based drug discovery: implementation and impact
Sandra A G Visser, Malin Aurell, Rhys D O Jones, et al.
European Journal of Heart Failure
|
July 20, 2023
Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction
Lars H Lund, Carolyn S P Lam, Patricia E Pizzato, et al.
Circulation
|
February 12, 2025
MYSTERY-HF: Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction: A Phase II Randomized Controlled Trial
Simon Braumann, Sascha Macherey-Meyer, Amin Polzin, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Clinical Drug Investigation
|
November 4, 2024
Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers
Mikael Sunnåker, Chandrali Bhattacharya, Karin Nelander, et al.
British Journal of Clinical Pharmacology
|
June 3, 2024
A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
Jane Knöchel, Vijender Panduga, Karin Nelander, et al.
British Journal of Clinical Pharmacology
|
August 12, 2024
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
Chandrali S Bhattacharya, Patricia Ely Pizzato, Maria Heijer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 18, 2025
A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis
Javier Armisen, Armando Flor, John Eriksson, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
October 22, 2020
INEXAS: A Phase 2 Randomized Trial of On-demand Inhaled Interferon Beta-1a in Severe Asthmatics
Christopher McCrae, Marita Olsson, Per Gustafson, et al.
American Journal of Respiratory and Critical Care Medicine
|
August 19, 2020
A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma
Ioannis Psallidas, Vibeke Backer, Piotr Kuna, et al.
Drug Discovery Today
|
June 4, 2013
Model-based drug discovery: implementation and impact
Sandra A G Visser, Malin Aurell, Rhys D O Jones, et al.
European Journal of Heart Failure
|
July 20, 2023
Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction
Lars H Lund, Carolyn S P Lam, Patricia E Pizzato, et al.
Circulation
|
February 12, 2025
MYSTERY-HF: Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction: A Phase II Randomized Controlled Trial
Simon Braumann, Sascha Macherey-Meyer, Amin Polzin, et al.
Page
of 1